Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 29

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 29
---
 and amount of executive compensation and grants of equity-based awards to executives, employees, consultants, and independent contractors. The Chief Executive Officer may make recommendations to our Compensation Committee concerning executive compensation and performance, but our Compensation Committee makes its own determination or recommendation to our Board with respect to the amount and components of compensation, including salary, bonus, target bonus percentages, and equity awards to executive officers, generally considering factors such as company performance, individual performance, and compensation paid by peer group companies.

Our executive compensation programs are designed to:

attract, motivate, and retain highly qualified executives;

align management and shareholder interests by tying a substantial percentage of executives’ compensation to financial performance of Lineage and its subsidiaries through the grant of equity awards;

reward superior performance by basing decisions regarding cash incentive compensation on the overall performance of executives; and

compensate executives at levels competitive with peer companies.

With respect to compensation matters for 2024, our Compensation Committee engaged Anderson to provide compensation consulting services and advice to our Compensation Committee, which included reviewing the peer group of companies used in evaluating executive and director compensation; providing information on executive and director compensation market trends; collecting and analyzing market pay data on director and executive compensation; and, providing recommendations on our executive and director compensation programs. Anderson also made recommendations to our Compensation Committee with respect to pay mix components such as salary, bonus, and equity awards, and the target market pay percentiles in which executive compensation should fall so we can be competitive in executive hiring and retention.

<div align='center'>-19-</div>

In reviewing each executive’s overall compensation, our Compensation Committee considers an aggregate view of base salary and bonus opportunities, equity incentive grants, and the dollar value of benefits and perquisites. These factors are balanced against our financial position and capital resources. In making 2024 compensation decisions, our Compensation Committee reviewed market data for each named executive officer’s position, from the following peer group companies:

| 4D Molecular Therapeutics, Inc. |     | Cartesian Therapeutics, Inc. |     | MeiraGTx Holdings plc       |
| Adverum Biotechnologies, Inc.   |     | Century Therapeutics, Inc.   |     | Nkarta, Inc.                |
| Agenus Inc.                     |     | Fate Therapeutics, Inc.      |     | Poseida Therapeutics, Inc.  |
| Altimmune, Inc.                 |     | Geron Corporation            |     | REGENEXBIO Inc.             |
| AnaptysBio,